NBTX

Nanobiotix S.A. ADR (NBTX) | Rumor.io

Nanobiotix

NBTX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,157

Bullish sentiment (50-day avg)0%

Price to earnings ratio-66.2

Market capitalization1.7B

Earnings per share-1.24

Dividend yield (TTM)—

Revenue (annual)29.6M

Net income (annual)-24M

Social

What share of all stock conversation is about NBTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

May 21

Nanobiotix S.A. ($NBTX) paused trading of its ordinary shares on Euronext Paris pending its global offering.
The trading halt is a result of the company's global offering.
$NBTX shares are down -6.0% pre-market.

Generated by AI

Sentiment

Of the messages about NBTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.99% -6.31
Bearish	—	—	—	7.01% +6.31

Bullish· Jul 10

$NBTX has a strong deal with Johnson & Johnson's Janssen Pharmaceutica NV, indicating undervaluation of 5x and a potential value of $250 million.
The stock has shown a reversal trend and has a good catalyst, with a potential price increase to the $10.00 area.
A global licensing and co-development agreement with Johnson & Johnson is expected to bring in record income and make the company profitable in the near term.

Bearish· May 5

The asset's debt-to-equity ratio is high, potentially threatening bankruptcy, with the company burning through $50M+ per year.
The asset's upcoming offering could lead to a significant price drop, potentially as low as $1-2 per share.
The asset's large float and history of manipulation make it a potentially volatile and shortable stock.

Generated by AI

Topics

Of the messages about NBTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	93.13%
Analysts	—	0%	0%	3.99%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.44%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	2.44%

Announcements· Jul 10

Nanobiotix S.A. ($NBTX) has announced a global licensing agreement with Janssen Pharmaceutica NV for the co-development and commercialization of NBTXR3, a potential first-in-class radioenhancer for cancer treatment.
The deal provides $30m in cash upfront, plus up to $30m in equity investment and up to $1.8bn in development, regulatory, and sales milestones, extending Nanobiotix's cash runway to 1Q 2024.
The partnership is expected to accelerate and expand Nanobiotix's mission to revolutionize cancer treatment, with NBTXR3's Phase 3 data expected in 2024 and potential approval and commercialization in the future.

Technical Analysis· May 5

$NBTX has formed an ascending triangle, which could lead to an explosive upwards move.
The stock is currently showing a flag pattern on the 5-minute chart, indicating a potential breakout.
$NBTX is holding above a major support zone of $3.7-$3.85, and a breakdown below $5.08-$5.15 could lead to a closer move towards $6.

Generated by AI

Community

Of the messages about NBTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	54.84%	34.04%
Newcomers	—	0%	45.16%	65.96%

Regulars· Jul 10

Nanobiotix has announced a license agreement with Janssen for the worldwide co-development and commercialization of NBTXR3, a potential first-in-class Radioenhancer for cancer treatment.
The agreement includes a $30m upfront payment, 30m equity investment, and up to $1.8bn in development and sales milestones, as well as a broader clinical trial program with MD Anderson Cancer Center.
The regulars are speculating about the potential implications of the agreement, including the possibility of future acquisition, and are referencing the recent collaborations and acquisitions in the M&A table.

Newcomers· May 17

$NBTX is being discussed due to its Phase 2 trial results, where the company announced a high treatment efficacy rate of 85.7% in a J&J-led study for its cancer treatment.
Some newcomers are excited about the potential of Nanobiotix's cancer treatment, a light-based therapy that could be a low-invasive treatment option.
TenNor Therapeutics, a company that is developing an antibiotic, has announced its IPO on the Hong Kong market, which could accelerate the development of new treatments.

Generated by AI

Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses obs

5d agoYahoo Finance UK

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisab

7d agoYahoo Finance UK

Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

Nanobiotix S.A. (NASDAQ:NBTX) reported September 14 results from all 24 patients in the dose-escalation and expansion portions of a Phase 1 study of JNJ-1900, also called NBTXR3, combined with repeat radiation. The study enrolled patients with inoperable, locoregionally recurrent non-small cell lung cancer. Nanobiotix S.A. (NASDAQ:NBTX) reported 79% one-year locoregional control at a median follow-up […]

12d agoYahoo Finance

Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug

14d agoInvesting.com

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (

16d agoca.finance.yahoo.com

Also Discussed

Investors talking about NBTX also mention

#	Name	Attention
1	UroGen Pharma Ltd.URGN	0%new
2	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
3	Pulse Biosciences IncPLSE	0%+0
4	GNFT - Genfit S.A.	——
5	Insight Enterprises, Inc.NSIT	0%0
6	BPTS - Biophytis S.A.	——
7	Wave Life Sciences Ltd.WVE	0%+0
8	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
9	Highland Opportunities and Income FundHFRO	0%0
10	Valneva SE Sponsored ADRVALN	0%new

Nanobiotix S.A. ADR

Healthcare
Biotechnology

Nanobiotix S.A. ADR is a biotechnology company focused on developing nanomedicine-based approaches for cancer treatment. The company’s current activities center on its proprietary physics-based technology platform, which is designed to enhance the effect of radiotherapy by targeting tumor cells more precisely. Its lead therapeutic candidate is being developed for use across several oncology settings, including solid tumors and other difficult-to-treat cancers. Nanobiotix serves the healthcare and life sciences market through research, clinical development, and potential commercialization of advanced cancer therapies, with a business model built around product candidates that integrate with existing treatment protocols. Headquartered in Paris, France, Nanobiotix operates as a clinical-stage company with a focus on oncology innovation and translational medical science.

Website

Location

60 rue de Wattignies

Paris, 75012

France

Social

What share of all stock conversation is about NBTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

May 21

Nanobiotix S.A. ($NBTX) paused trading of its ordinary shares on Euronext Paris pending its global offering.
The trading halt is a result of the company's global offering.
$NBTX shares are down -6.0% pre-market.

Generated by AI

Sentiment

Of the messages about NBTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.99% -6.31
Bearish	—	—	—	7.01% +6.31

Bullish· Jul 10

$NBTX has a strong deal with Johnson & Johnson's Janssen Pharmaceutica NV, indicating undervaluation of 5x and a potential value of $250 million.
The stock has shown a reversal trend and has a good catalyst, with a potential price increase to the $10.00 area.
A global licensing and co-development agreement with Johnson & Johnson is expected to bring in record income and make the company profitable in the near term.

Bearish· May 5

The asset's debt-to-equity ratio is high, potentially threatening bankruptcy, with the company burning through $50M+ per year.
The asset's upcoming offering could lead to a significant price drop, potentially as low as $1-2 per share.
The asset's large float and history of manipulation make it a potentially volatile and shortable stock.

Generated by AI

Topics

Of the messages about NBTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	93.13%
Analysts	—	0%	0%	3.99%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.44%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	2.44%

Announcements· Jul 10

Nanobiotix S.A. ($NBTX) has announced a global licensing agreement with Janssen Pharmaceutica NV for the co-development and commercialization of NBTXR3, a potential first-in-class radioenhancer for cancer treatment.
The deal provides $30m in cash upfront, plus up to $30m in equity investment and up to $1.8bn in development, regulatory, and sales milestones, extending Nanobiotix's cash runway to 1Q 2024.
The partnership is expected to accelerate and expand Nanobiotix's mission to revolutionize cancer treatment, with NBTXR3's Phase 3 data expected in 2024 and potential approval and commercialization in the future.

Technical Analysis· May 5

$NBTX has formed an ascending triangle, which could lead to an explosive upwards move.
The stock is currently showing a flag pattern on the 5-minute chart, indicating a potential breakout.
$NBTX is holding above a major support zone of $3.7-$3.85, and a breakdown below $5.08-$5.15 could lead to a closer move towards $6.

Generated by AI

Community

Of the messages about NBTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	54.84%	34.04%
Newcomers	—	0%	45.16%	65.96%

Regulars· Jul 10

Nanobiotix has announced a license agreement with Janssen for the worldwide co-development and commercialization of NBTXR3, a potential first-in-class Radioenhancer for cancer treatment.
The agreement includes a $30m upfront payment, 30m equity investment, and up to $1.8bn in development and sales milestones, as well as a broader clinical trial program with MD Anderson Cancer Center.
The regulars are speculating about the potential implications of the agreement, including the possibility of future acquisition, and are referencing the recent collaborations and acquisitions in the M&A table.

Newcomers· May 17

$NBTX is being discussed due to its Phase 2 trial results, where the company announced a high treatment efficacy rate of 85.7% in a J&J-led study for its cancer treatment.
Some newcomers are excited about the potential of Nanobiotix's cancer treatment, a light-based therapy that could be a low-invasive treatment option.
TenNor Therapeutics, a company that is developing an antibiotic, has announced its IPO on the Hong Kong market, which could accelerate the development of new treatments.

Generated by AI

Nanobiotix

Social

May 21

Bullish· Jul 10

Bearish· May 5

Announcements· Jul 10

Technical Analysis· May 5

Regulars· Jul 10

Newcomers· May 17

Can J&J’s Partnership Drive More Upside for Nanobiotix?

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

Voting Rights and Shares Capital of the Company

Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

Also Discussed

Nanobiotix S.A. ADR

Company Information

Location

Can J&J’s Partnership Drive More Upside for Nanobiotix?

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

Voting Rights and Shares Capital of the Company

Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

Also Discussed

Social

May 21

Bullish· Jul 10

Bearish· May 5

Announcements· Jul 10

Technical Analysis· May 5

Regulars· Jul 10

Newcomers· May 17